Live feed19:30:00·14mPRReleasevia QuantisnowZipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung CancerByQuantisnow·Wall Street's wire, on your screen.CGEM· Cullinan Therapeutics Inc.Health Care
